Skip to main content

New story in Health from Time: Gilead is Testing Inahalable Remdesivir, as a Possible Replacement for the Intravenous Form of the Drug



On June 22, Gilead, the California-based pharmaceutical company that makes remdesivir, said it will start testing an inhaled form of its experimental COVID-19 therapy. Currently, patients can only receive the drug by IV infusion provided under the supervision of medical experts.

In a letter published to the company’s website, chairman and CEO David O’Day said Gilead will begin screening healthy volunteers this week to participate in a phase 1 trial of a nasally administered version of remdesivir. Phase 1 trials are designed to determine the safety of an experimental treatment, before moving on to studies of its effectiveness.

The IV-administered form of remdesivir is still being tested, along with other drugs, among the sickest patients who are hospitalized for COVID-19. Early data from those studies suggest that remdesivir can help patients recover more quickly compared to patients not receiving the infusions. Because the drug is not yet approved; patients can only receive it either by participating in a trial or, if they are severely ill, through an emergency use authorization from the U.S. Food and Drug Administration (which allows doctors to prescribe the drug if no other therapies have worked).

The company also announced in its June 22 letter that it will investigate using remdesivir in COVID-19 patients with less severe symptoms, in the hopes that introducing the drug earlier in the disease may help some people avoid the worst symptoms of respiratory distress and failure.

Popular posts from this blog

New story in Health from Time: COVID-19 Has Been ‘Apocalyptic’ for Public Transit. Will Congress Offer More Help?

While trying to get to work over the past few months, Brittany Williams, a Seattle home care worker, has often been passed by two or three buses before one stops to let her board. Buses in her area that once carried anywhere from about 50 to 100 passengers have been limited to between 12 and 18 to prevent overcrowding in response to coronavirus, and Williams’ commute, typically a half-hour ride, now takes more than double that time. Other Seattle transit riders have described budgeting as much as an extra hour per trip to account for the reduced capacity, eating into their time at work, school or with family. Even with the ridership limits in place, Williams, 34, doesn’t feel safe on public transit. Some passengers don’t wear face coverings, and bus drivers sometimes ignore capacity limits, she says. On one ride with her seven-year-old son, she decided to get off at a stop far from her home after a driver allowed a crowd of people to board. “It’s very trying. I’ll put...

New story in Health from Time: 265 Million People Could Face Hunger in ‘Unprecedented’ Crisis, World Food Program Expert Warns

The world faces an “unprecedented” food crisis due to the COVID-19 pandemic, which has caused both severe job losses and major disruptions in food supply chains, the U.N. World Food Programme’s Chief Economist warns. “When you have these severe job losses, or you have big lockdowns, that means that those people become vulnerable,” Arif Husain tells TIME. An estimated 265 million people could go hungry in 2020, nearly double the 2019 figures, according to WFP’s projection in April. As millions around the world are losing their jobs or seeing their incomes cut , it’s increasingly difficult for them to afford food, Husain says. At the same time, lockdown measures and trade restrictions are making it harder to transport food from where it’s produced to where it’s needed, resulting in food going to waste in the field. Refugees and people in conflict zones like Yemen, Syria, and Burkina Faso and those already living hand-to-mouth prior to the coronavirus outbreak are parti...

New story in Health from Time: Hundreds Asked to Self-Quarantine in D.C. After Possible COVID-19 Exposure at Church

(WASHINGTON) — Several hundred people are being asked to self-quarantine after potential exposure to the first confirmed case of the new coronavirus in the nation’s capital, identified as the rector of a prominent Episcopal church. District of Columbia Mayor Muriel Bowser said Monday that anyone who entered Christ Church Georgetown on Feb. 24 or between Feb. 28 and March 3 is requested to self-quarantine for two weeks from the date of their entrance to the church. Officials on Saturday had announced the district’s first positive test, but identified the victim only as a man in his 50s. A second local positive test involves a man who visited the Washington area from Nigeria, but he was being hospitalized in Maryland. Rev. Timothy Cole, the church rector, announced Sunday that he was the person whom city officials had been referring to as “patient 1.” He remains hospitalized in stable condition and the church has canceled all activities until further notice. Dr. Anjali Ta...